28 related articles for article (PubMed ID: 9072308)
1. An evaluation of potential signals for ventricular arrhythmia and cardiac arrest with dolasetron, ondansetron, and granisetron in the fda combined spontaneous reporting system/adverse event reporting system.
Schnell FM; Coop AJ
Curr Ther Res Clin Exp; 2005 Sep; 66(5):409-19. PubMed ID: 24790242
[TBL] [Abstract][Full Text] [Related]
2. Reappraisal of the role of dolasetron in prevention and treatment of nausea and vomiting associated with surgery or chemotherapy.
Roberts SM; Bezinover DS; Janicki PK
Cancer Manag Res; 2012; 4():67-73. PubMed ID: 22427733
[TBL] [Abstract][Full Text] [Related]
3. Electrocardiographic findings of palonosetron in cancer patients.
Gonullu G; Demircan S; Demirag MK; Erdem D; Yucel I
Support Care Cancer; 2012 Jul; 20(7):1435-9. PubMed ID: 21773677
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials.
Viani GA; Afonso SL; Stefano EJ; De Fendi LI; Soares FV
BMC Cancer; 2007 Aug; 7():153. PubMed ID: 17686164
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab and breast cancer: developments and current status.
Tokunaga E; Oki E; Nishida K; Koga T; Egashira A; Morita M; Kakeji Y; Maehara Y
Int J Clin Oncol; 2006 Jun; 11(3):199-208. PubMed ID: 16850126
[TBL] [Abstract][Full Text] [Related]
6. Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery.
Balfour JA; Goa KL
Drugs; 1997 Aug; 54(2):273-98. PubMed ID: 9257083
[TBL] [Abstract][Full Text] [Related]
7. [Value of the combination of oral ondansetron with methylprednisolone as soon as the first cure in mild emetogenic chemotherapy. Groupe français d'étude de l'ondansétron].
Coiffier B; Khayat D; Misset JL; Votan B
Bull Cancer; 1997 Aug; 84(8):781-7. PubMed ID: 9339181
[TBL] [Abstract][Full Text] [Related]
8. Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study Group.
Rubenstein EB; Gralla RJ; Hainsworth JD; Hesketh PJ; Grote TH; Modiano MR; Khojasteh A; Kalman LA; Benedict CR; Hahne WF
Cancer; 1997 Mar; 79(6):1216-24. PubMed ID: 9070501
[TBL] [Abstract][Full Text] [Related]
9. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
Eisenberg P; Figueroa-Vadillo J; Zamora R; Charu V; Hajdenberg J; Cartmell A; Macciocchi A; Grunberg S;
Cancer; 2003 Dec; 98(11):2473-82. PubMed ID: 14635083
[TBL] [Abstract][Full Text] [Related]
10. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
Hesketh P; Navari R; Grote T; Gralla R; Hainsworth J; Kris M; Anthony L; Khojasteh A; Tapazoglou E; Benedict C; Hahne W
J Clin Oncol; 1996 Aug; 14(8):2242-9. PubMed ID: 8708713
[TBL] [Abstract][Full Text] [Related]
11. [Prophylaxis of nausea and vomiting after thyroid surgery: comparison of oral and intravenous dolasetron with intravenous droperidol and placebo].
Danner K; Becker HG; Best B; Madler C
Anasthesiol Intensivmed Notfallmed Schmerzther; 2001 Jul; 36(7):425-30. PubMed ID: 11496617
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy.
Burris H; Hesketh P; Cohn J; Moriconi W; Ryan T; Friedman C; Fitts D
Cancer J Sci Am; 1996; 2(2):85-90. PubMed ID: 9166505
[TBL] [Abstract][Full Text] [Related]
13. Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Oral Dolasetron Dose Response Study Group.
Grote TH; Pineda LF; Figlin RA; Pendergrass KB; Hesketh PJ; Karlan BY; Reeves JA; Porter LL; Benedict CR; Hahne WF
Cancer J Sci Am; 1997; 3(1):45-51. PubMed ID: 9072308
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]